Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase l Open-Label, Dose Escalation and Cohort Expansion Study, to Assess the Safety and Activity of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC) and Advanced or Metastatic Ovarian Clear Cell Carcinoma (OCCC)

NCT02837991 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT02837991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02837991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase l Open-Label, Dose Escalation and Cohort Expansion Study, to Assess the Safety and Activity of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC) and Advanced or Metastatic Ovarian Clear Cell Carcinoma (OCCC)
Lead sponsor
Celldex Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
June 30, 2016
Completion date
November 16, 2018
Enrollment
16 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

clear-cell renal cell carcinoma, kidney neoplasms, metastatic renal cell carcinoma, ovarian clear cell carcinoma, papillary renal cell carcinoma, renal cell carcinoma (rcc)